Изменения состояния жизненно важных систем организма при Long-COVID-19

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Длительный COVID-19 или Long-COVID-19 является затяжным заболеванием, которое продолжает изучаться. Представлены данные по эпидемиологии, основным симптомам, характерным для Long-COVID-19. Обсуждаются вопросы, связанные с патогенезом заболевания. При этом особое внимание уделяется процессу воспаления (в том числе эндотелия сосудистой стенки), состоянию иммунной системы (цитокиновый шторм), системе гемостаза (механизм развития микроангиопатии и тромбоза) и окислительному стрессу. При анализе особое место отводится нарушениям ЦНС, включая органические поражения мозга, и расстройствам когнитивных функций. Кроме того, описаны известные к настоящему времени осложнения со стороны сердечно-сосудистой системы и органов дыхания. Лечение и реабилитация больных Long-COVID-19 является не только медицинской, но и значительной социальной проблемой.

Об авторах

Б. И. Кузник

Читинская государственная медицинская академия; Инновационная клиника “Академия здоровья”

Email: ni_chalisova@mail.ru
Россия, Чита; Россия, Чита

К. Г. Шаповалов

Читинская государственная медицинская академия

Email: ni_chalisova@mail.ru
Россия, Чита

Н. И. Чалисова

Институт физиологии им. И.П. Павлова РАН; Санкт-Петербургский институт биорегуляции и геронтологии

Автор, ответственный за переписку.
Email: ni_chalisova@mail.ru
Россия, Санкт-Петербург; Россия, Санкт-Петербург

Список литературы

  1. Кузник Б.И., Хавинсон В.Х., Линькова Н.С. COVID-19: влияние на иммунитет, систему гемостаза и возможные пути коррекции // Успехи физиол. наук. 2020а. Т. 51. № 4. С. 51–63.
  2. Кузник Б.И., Хавинсон В.Х., Лукьянов С.А. и др. Влияние тоцилизумаба и тималина на системное воспаление у больных COVID-19 // Врач. 2020б. Т. 31. № 11. С. 87–96.
  3. Любавина Н.А., Сальцев С.Г., Меньков Н.В. и др. Иммунологические подходы к лечению новой коронавирусной инфекции (обзор) // Соврем. технол. мед. 2021. Т. 13. № 3. С. 81–101.
  4. Симарова И.Б., Переходов С.Н., Буланов А.Ю. Геморрагические осложнения новой коронавирусной инфекции: актуальная клиническая проблема // Тромб, гемост. реол. 2021. № 3. С. 12–15.
  5. Слуханчук Е.В., Бицадзе В.О., Хизроева Ю.К. и др. COVID-19 и тромботическая микроангиопатия // Акуш. гинекол. репрод. 2021. Т. 15. № 6. С. 639–657.
  6. Adeloye D., Elneima O., Daines L. et al. The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease // Lancet Respir. Med. 2021. V. 9. № 12. P. 1467–1478.
  7. Agyeman A.A., Chin K.L., Landersdorfer C.B. et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis // Mayo Clin. Proc. 2020. V. 95. № 8. P. 1621–1631.
  8. Alberti P., Beretta S., Piatti M. et al. Guillain–Barre syndrome related to COVID-19 infection // Neurol. Neuroimmunol. Neuroinflamm. 2020. V. 7. № 4. P. e741.
  9. Bohmwald K., Gálvez N.M.S., Ríos M., Kalergis A.M. Neurologic alterations due to respiratory virus infections // Front. Cell. Neurosci. 2018. V. 12. P. 386.
  10. Bornstein S.R., Voit-Bak K., Donate T. et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: is there a role for extracorporeal apheresis // Mol. Psychiatry. 2021. V. 27. № 1. P. 34–37.
  11. Calabrese F., Pezzuto F., Fortarezza F. et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of european pulmonary pathologists // Virchows Arch. 2020. V. 477. № 3. P. 359–372.
  12. Callard F., Perego E. How and why patients made Long Covid // Soc. Sci. Med. 2021. V. 268. P. 113426.
  13. Carvalho-Schneider C., Laurent E., Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptoms onset // Clin. Microbiol. Infect. 2021. V. 27. P. 258–263.
  14. Chen C., Amelia A., Ashdown G.W. et al. Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection // Mol. Med. 2021. V. 27. № 1. P. 160–167.
  15. Chippa V., Aleem A., Anjum F. Post acute coronavirus (COVID-19) syndrome. Treasure Island: StatPearls Publ., 2022.
  16. Crook H., Raza S., Nowell J. et al. Long covid-mechanisms, risk factors, and management // BMJ. 2021. V. 374. P. n1648.
  17. Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies // Clin. Med. 2021. V. 21. № 1. P. e63–e67.
  18. DosSantos M.F., Devalle S., Aran V. et al. Neuromechanisms of SARS-CoV-2: a review // Front. Neuroanat. 2020. V. 14. P. 37–42.
  19. Espinosa Rodríguez P., Martínez Aguilar A., Ripoll Muñoz M.P., Rodríguez Navarro M.Á. Long COVID: is it really myalgic encephalomyelitis? Bibliographic review and considerations // Semergen. 2022. V. 48. № 1. P. 63–69.
  20. Estiri H., Strasser Z.H., Brat G.A. et al. Evolving phenotypes of non-hospitalized patients that indicate long COVID // BMC Med. 2021. V. 19. P. 249.
  21. Frija-Masson J., Debray M.P., Gilbert M. et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection // Eur. Respir. J. 2020. V. 56. № 2. P. 2001754.
  22. Garg S., Garg M., Prabhakar N. et al. Unraveling the mystery of Covid-19 cytokine storm: from skin to organ systems // Dermatol. Ther. 2020. V. 33. № 6. P. 1385–1389.
  23. Garg M., Maralakunte M., Garg S. et al. The conundrum of “Long-COVID-19”: a narrative review // Int. J. Gen. Med. 2021. V. 14. P. 2491–2506.
  24. Goh K.J., Choong M.C., Cheong E.H. et al. Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection // Ann. Acad. Med. Singap. 2020. V. 49. № 3. P. 108–118.
  25. Graham E.L., Clark J.R., Orban Z.S. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers” // Ann. Clin. Transl. Neurol. 2021. V. 8. № 5. P. 1073–1085.
  26. Hadjadj J., Yatim N., Barnabei L. et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients // Science. 2020. V. 369. № 6504. P. 718–724.
  27. Haidar M.A., Jourdi H., Haj Hassan Z. et al. Neurological and neuropsychological changes associated with SARS-CoV-2 infection: new observations new mechanisms // Neuroscientist. 2021. V. 2021. Iss. 1073858420984106.
  28. Haidar M.A., Shakkour Z., Reslan M.A. et al. SARS-CoV-2 involvement in central nervous system tissue damage // Neural Regen. Res. 2022. V. 17. № 6. P. 1228–1239.
  29. Huang N., Pérez P., Kato T. et al. SARS-CoV-2 infection of the oral cavity and saliva // Nat. Med. 2021. V. 27. P. 892–903.
  30. Ilonzo N., Kumar S., Borazan N. et al. Endotheliitis in coronavirus disease-19-positive patients after extremity amputation for acute thrombotic events // Ann. Vasc. Surg. 2021. V. 72. P. 209–215.
  31. Kananeh M.F., Thomas T., Sharma K. et al. Arterial and venous strokes in the setting of COVID-19 // J. Clin. Neurosci. 2020. V. 79. P. 60–66.
  32. Kanberg N., Ashton N.J., Andersson L.M. et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 // Neurology. 2020. V. 95. P. e1754–e1759.
  33. Khavinson V., Linkova N., Dyatlova A. et al. Peptides: prospects for use in the treatment of COVID-19 // Molecules. 2020. V. 25. № 19. P. 4389–4393.
  34. Khavinson V.Kh., Kuznik B.I., Trofimova S.V. et al. Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19 // Stem Cell Rev. Rep. 2021. V. 17. № 1. P. 285–290.
  35. Komaroff A.L., Lipkin W.I. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrom // Trends Mol. Med. 2021. V. 27. № 9. P. 895–906.
  36. Lingel H., Meltendorf S., Billing U. et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals // J. Autoimmun. 2021. V. 122. P. 102682.
  37. Logue J.K., Franko N.M., McCulloch D.J. et al. Sequelae in adults at 6 months after COVID-19 infection // JAMA Netw. Open. 2021. V. 4. № 2. P. e210830.
  38. López Castro J. Post-COVID-19 syndrome (PC19S): chronic reactive endotheliitis and disseminated vascular disease // Acta Med. Port. 2020. V. 33. № 12. P. 859–864.
  39. Lu J.Q., Lu J.Y., Wang W. et al. Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19 // EBioMedicine. 2022. V. 76. P. 103821.
  40. Lucas C., Wong P., Klein J. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 // Nature. 2020. V. 584. P. 463–469.
  41. Mahase E. Covid-19: what do we know about “long covid”? // BMJ. 2020. V. 370. P. m2815.
  42. Mahdi A., Collado A., Tengbom J. et al. Erythrocytes induce vascular dysfunction in COVID-19 // JACC Basic Transl. Sci. 2022. V. 7. № 3. P. 193–204.
  43. Mantovani E., Mariotto S., Gabbiani D. et al. Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors? // Neurovirol. 2021. V. 27. № 4. P. 631–637.
  44. Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan China // JAMA Neurol. 2020. V. 77. P. 683–690.
  45. Maracaja L., Khanna A.K., Royster R. et al. Selective lobe ventilation and a novel platform for pulmonary drug delivery // J. Cardiothorac. Vasc. Anesth. 2021. V. 35. № 11. P. 3416–3422.
  46. Meier I.B., Vieira Ligo Teixeira C., Tarnanas I. et al. Neurological and mental health consequences of COVID-19: potential implications for well-being and labour force // Brain Commun. 2021. V. 3. № 1. P. fcab012.
  47. Meinhardt J., Radke J., Dittmayer C. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 // Nat. Neurosci. 2021. V. 24. P. 168–175.
  48. Moriguchi T., Harii N., Goto J. et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 // Int. J. Infect. Dis. 2020. V. 94. P. 55–58.
  49. Morris G., Bortolasci C.C., Puri B.K. et al. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all? // Cytokine. 2021. V. 144. P. 155593.
  50. Nassau D.E., Best J.C., Kresch E. et al. Impact of the SARS-CoV-2 virus on male reproductive health // BJU Int. 2022. V. 129. № 2. P. 143–150.
  51. Nguyen N.N., Hoang V.T., Lagier J.C. et al. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients // Clin. Microbiol. Infect. 2021. V. 27. № 6. P. 931–932.
  52. Okada Y., Yoshimura K., Toya S., Tsuchimochi M. Pathogenesis of taste impairment and salivary dysfunction in COVID-19 patients // Jpn. Dent. Sci. Rev. 2021. V. 57. P. 111–122.
  53. Pazuhina E., Angreeva M., Spiridonova E. et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective // BMC Med. 2022. V. 20. P. 244.
  54. Pezzini A., Padovani A. Lifting the mask on neurological manifestations of COVID-19 // Nat. Rev. Neurol. 2020. V. 16. № 11. P. 636–644.
  55. Pierce J.D., Shen Q., Cintron S.A. et al. Post-COVID-19 syndrome // Nurs. Res. 2022. V. 71. № 2. P. 164–174.
  56. Premraj L., Kannapadi N.V., Briggs J. et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis // J. Neurol. Sci. 2022. V. 434. P. 120162.
  57. Rubin R. As their numbers grow, COVID-19 “long haulers” stump experts // JAMA. 2020. V. 324. P. 1381–1383.
  58. Scordo K.A., Richmond M.M., Munro N. Post-COVID-19 syndrome: theoretical basis, identification, and management // AACN Adv. Crit. Care. 2021. V. 32. № 2. P. 188–194.
  59. Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline // BMJ. 2021. V. 372. P. n136.
  60. Shi H., Zuo Y., Navaz S. et al. Endothelial cell-activating antibodies in COVID-19 // Arth. Rheumatol. 2022. V. 74. P. 1132–1138.
  61. Silva Andrade B., Siqueira S., Soares W.R.A. et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms // Viruses. 2021. V. 13. № 4. P. 700–710.
  62. Singer-Cornelius T., Cornelius J., Oberle M. et al. Objective gustatory and olfactory dysfunction in COVID-19 patients: a prospective cross-sectional study // Eur. Arch. Otorhinolaryngol. 2021. V. 278. № 9. P. 3325–3332.
  63. Strauss S.B., Lantos J.E., Heier L.A. et al. Olfactory bulb signal abnormality in patients with COVID-19 who present with neurologic symptoms // AJNR. 2020. V. 41. P. 1882–1887.
  64. Su Y., Yuan D., Chen D.G. et al. Multiple early factors anticipate post-acute COVID-19 sequelae // Cell. 2022. V. 185. № 5. P. 881–895.
  65. Takahashi T., Ota M., Numata Y. et al. Relationships between the fear of COVID-19 scale and regional brain atrophy in mild cognitive impairment // Acta Neuropsychiatrica. 2022. V. 34. P. 153–162.
  66. Tian T., Wu J., Chen T. et al. Long-term follow-up of dynamic brain changes in patients recovered from COVID-19 without neurological manifestations // JCI Insight. 2022. V. 7. № 4. P. e155827.
  67. Torres-Castro R., Vasconcello-Castillo L., Alsina-Restoy X. et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis // Pulmonology. 2021. V. 27. № 4. P. 328–337.
  68. Tran V.-T., Riveros C., Clepier B. et al. Development and validation of the Long coronavirus disease (COVID) symptom and impact tools, a set of patient-reported instruments constructed from patients’ lived experience // Clin. Infect. Dis. 2022. V. 74. P. 278–287.
  69. Tremblay M.-E., Madore C., Bordeleau M. et al. Neuropathobiology of COVID-19: the role for glia // Front. Cell. Neurosci. 2020. V. 14. P. 592214.
  70. Verity R., Okell L.C., Dorigatti I. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis // Lancet Infect. Dis. 2020. V. 20. № 6. P. 669–677.
  71. Wallukat G., Hohberger B., Wenzel K. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms // J. Transl. Autoimmun. 2021. V. 4. P. 100100.
  72. Wang F., Kream R.M., Stefano G.B. Long-term respiratory and neurological sequelae of COVID-19// Med. Sci. Monit. 2020a. V. 26. P. e928996.
  73. Wang F., Nie J., Wang H. et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia // J. Infect. Dis. 2020b. V. 221. № 11. P. 1762–1769.
  74. Wong A.W., Shah A.S., Johnston J.C. et al. Patient-reported outcome measures after COVID-19: a prospective cohort study // Eur. Respir. J. 2020. V. 56. № 5. P. 2003276.
  75. Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19 // Nat. Med. 2022. V. 28. № 3. P. 583–590.
  76. Xiong Q., Xu M., Li J. et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study // Clin. Microbiol. Infect. 2021. V. 27. P. 89–95.
  77. Yap J.K.Y., Moriyama M., Iwasaki A. Inflammasomes and pyroptosis as therapeutic targets for COVID-19 // J. Immunol. 2020. V. 205. № 2. P. 307–312.
  78. Ye G., Pan Z., Pan Y. et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation // J. Infect. 2020. V. 80. № 5. P. e14–e17.
  79. Yelin D., Margalit I., Yahav D. et al. Long COVID-19 – it’s not over until? // Clin. Microbiol. Infect. 2021. V. 27. № 4. P. 506–508.
  80. Zhou H., Lu S., Chen J. et al. The landscape of cognitive function in recovered COVID-19 patients // J. Psychiatr. Res. 2020. V. 129. P. 98–102.
  81. Zuo Y., Estes S.K., Ali R.A. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 // Sci. Transl. Med. 2020. V. 12. № 570. P. eabd3876.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать
2.

Скачать (449KB)
Метаданные

© Б.И. Кузник, К.Г. Шаповалов, Н.И. Чалисова, 2023

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах